{"id":387422,"date":"2020-11-24T07:03:27","date_gmt":"2020-11-24T12:03:27","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=387422"},"modified":"2020-11-24T07:03:27","modified_gmt":"2020-11-24T12:03:27","slug":"g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\/","title":{"rendered":"G1 Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020"},"content":{"rendered":"
\n

RESEARCH TRIANGLE PARK, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX<\/a>), a clinical-stage oncology company, today announced that incoming Chief Executive Officer Jack Bailey and Chief Medical Officer and Senior Vice President, R&D Raj Malik, M.D. will present a company update at the Evercore ISI 3rd<\/sup> Annual HealthCONx Conference on December 3, 2020 at 1:00 p.m. ET.<\/p>\n

To access the live and archived webcast of the presentation, please visit the Events & Presentations page<\/a> of the G1 website<\/a>.<\/p>\n

\n About G1 Therapeutics<\/strong>
\n
G1 Therapeutics, Inc.\u00a0is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel therapies: trilaciclib<\/a> is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy; rintodestrant<\/a> is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. In 2020, the company out-licensed global development and commercialization rights to its differentiated oral CDK4\/6 inhibitor, lerociclib.<\/p>\n

G1 Therapeutics\u00a0is based in\u00a0Research Triangle Park, N.C.\u00a0For additional information, please visit\u00a0www.g1therapeutics.com<\/a>\u00a0and follow us on Twitter\u00a0@G1Therapeutics<\/a>.<\/p>\n

\n Contact:<\/strong>
\n
Jeff Macdonald
G1 Therapeutics, Inc.
Senior Director, Investor Relations & Corporate Communications
919-907-1944
jmacdonald@g1therapeutics.com<\/a><\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

RESEARCH TRIANGLE PARK, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that incoming Chief Executive Officer Jack Bailey and Chief Medical Officer and Senior Vice President, R&D Raj Malik, M.D. will present a company update at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020 at 1:00 p.m. ET. To access the live and archived webcast of the presentation, please visit the Events & Presentations page of the G1 website. About G1 Therapeutics G1 Therapeutics, Inc.\u00a0is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel … <\/p>\n

Continue reading “G1 Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-387422","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nG1 Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"G1 Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"RESEARCH TRIANGLE PARK, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that incoming Chief Executive Officer Jack Bailey and Chief Medical Officer and Senior Vice President, R&D Raj Malik, M.D. will present a company update at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020 at 1:00 p.m. ET. To access the live and archived webcast of the presentation, please visit the Events & Presentations page of the G1 website. About G1 Therapeutics G1 Therapeutics, Inc.\u00a0is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel … Continue reading "G1 Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-24T12:03:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTE3MyMzODQxMDI3IzIwMjkxMDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"G1 Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020\",\"datePublished\":\"2020-11-24T12:03:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\\\/\"},\"wordCount\":229,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTE3MyMzODQxMDI3IzIwMjkxMDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\\\/\",\"name\":\"G1 Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTE3MyMzODQxMDI3IzIwMjkxMDc=\",\"datePublished\":\"2020-11-24T12:03:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTE3MyMzODQxMDI3IzIwMjkxMDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTE3MyMzODQxMDI3IzIwMjkxMDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"G1 Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"G1 Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\/","og_locale":"en_US","og_type":"article","og_title":"G1 Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020 - Market Newsdesk","og_description":"RESEARCH TRIANGLE PARK, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that incoming Chief Executive Officer Jack Bailey and Chief Medical Officer and Senior Vice President, R&D Raj Malik, M.D. will present a company update at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020 at 1:00 p.m. ET. To access the live and archived webcast of the presentation, please visit the Events & Presentations page of the G1 website. About G1 Therapeutics G1 Therapeutics, Inc.\u00a0is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel … Continue reading \"G1 Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-24T12:03:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTE3MyMzODQxMDI3IzIwMjkxMDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"G1 Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020","datePublished":"2020-11-24T12:03:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\/"},"wordCount":229,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTE3MyMzODQxMDI3IzIwMjkxMDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\/","name":"G1 Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTE3MyMzODQxMDI3IzIwMjkxMDc=","datePublished":"2020-11-24T12:03:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTE3MyMzODQxMDI3IzIwMjkxMDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTE3MyMzODQxMDI3IzIwMjkxMDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-on-december-3-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"G1 Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387422","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=387422"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387422\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=387422"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=387422"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=387422"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}